KLOX Technologies announces the sale of its in-office whitening kit and
teeth-whitening pen businesses to Valeant Pharmaceuticals International, Inc.
KLOX Technologies to focus its innovative biophotonic technology and resources
on medically focused solutions in dermatology, tissue repair and dentistry
LAVAL, QC, Nov. 29, 2012 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the
"Company") is pleased to announce that it has entered into an agreement for
the sale (the "Sale") of its professional in-dentists-office whitening kit
business as well as its teeth-whitening pen business ("Business") to Valeant
Pharmaceuticals International, Inc. (NYSE/TSX: VRX), which will be managed by
its dental affiliate OraPharma, Inc. ("Valeant"). As part of the Sale, KLOX
is assigning to Valeant its rights in the Business. Valeant is planning to
launch the products in the U.S. in early 2013 and is planning a smooth
transition with existing partners. Financial terms include an upfront payment
and a double-digit royalty stream based on product sales during the next 10
"We are pleased to have concluded the transaction with Valeant, a highly
regarded company. Valeant has conveyed its commitment towards taking our
product lines to their full potential through their well-established
commercial capabilities in the United States and around the world", said Dr.
Lise Hébert, President & CEO of KLOX. "This is a very exciting opportunity
for all of us and at KLOX we will continue building our value-creation
strategy and invest in our innovation and development for the advancement of
medical solutions in the fields of dermatology, dentistry and tissue repair.
Our European registration trial to treat moderate-to-severe acne is scheduled
to complete in a few weeks and the evaluation of the safety and efficacy of
our devices to treat unresponsive chronic wounds in America and Europe is
underway. The next 24 months will be important for KLOX in the delivery to the
market of brand new solutions to address what still today remain unmet medical
needs in the treatment of acne and the advanced wound care fields", she
"This acquisition is a very good strategic fit for Valeant and for OraPharma,
as Valeant continues to enhance its commercial capabilities within the dental
market segment," said Mr. Steven Sembler, Senior Vice-President at OraPharma.
"KLOX has successfully developed and brought forward innovative technology and
clinically meaningful products that represent a significant commercial
opportunity in the whitening field in many geographies around the world. We
immediately want to build upon those capabilities and use both our commercial
organization and network of partners to leverage them into attractive product
propositions and to create additional value for both patients and clinicians,"
About KLOX Technologies: Leveraging light-based biophotonic technologies
KLOX is a privately-owned company focused on the development and
commercialization of a unique, non-invasive biophotonic technology using a
primary device consisting of a multiple LED lighting system that interacts
with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics
and medical devices are destined for the rapidly growing aesthetics, dental,
dermatological and medical markets. Its dentistry portfolio included
innovative teeth whitening treatments like FAST&MILD™ and LifeSmile™.
Treatments for periodontitis are also currently under development for medical
About the Business
FAST&MILD™: Effective, non-invasive and affordable
FAST&MILD™ is positioned to rapidly take a strong foothold in the teeth
whitening market. It is an advanced chair-side whitening system that uses
biophotonic technology to whiten teeth naturally. This unique TRUE light
activated system delivers result in as a little as 30 minutes, with virtually
no sensitivity. The reduced treatment time translates into a gentler procedure
providing you with a brilliant, healthy looking smile.
FAST&MILD™ is highly competitive compared to other teeth whitening products
in the market today. From the dentist's perspective, it is capital efficient,
with no capital investment required. The procedure can be completed in about
half the time required for competitive products, allowing for increased
efficiency in dentist's office.
LifeSmile™: a whitening pen with unique features
LifeSmile™ by KLOX Technologies advanced teeth brightening pen is a
revolutionary teeth whitening pen designed by dentists to quickly and
effectively clean away surface stains from your teeth, at affordable prices.
Conceived for life on the go, whitening your teeth has never been easier!
LifeSmile™ is no bigger than a pen, its sleek compact design means it can go
anywhere you do.
In the dermatology segment, KLOX's skin rejuvenation product SKR-1 is in
regulatory compliance in Canada, United States and Europe and is now ready to
be fully commercialized. In addition, KLOX has also developed a promising Acne
treatment system (AC-1), which is currently in a final registration trial
towards approval in Europe. The trial is near completion with an encouraging
safety profile and the data is planned for the first quarter of 2013.
Finally, KLOX is developing (WH-1), an innovative light-based treatment for
the multi-billion dollar advanced wound care market. Its proprietary
technology, which has been fundamentally designed to operate as a light
enhancing technology, combines multi-LED light phototherapy effect, an
externally applied oxidant and certain chromophores designed to enhance
breakdown of oxidant as well as skin's light absorption. The system is being
investigated to treat pressure sores, diabetic and venous leg ulcers with the
goal to significantly accelerate healing in a favorable environment.
For further information on KLOX, please visit the Company's website:
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational
specialty pharmaceutical company that develops, manufactures and markets a
broad range of pharmaceutical products primarily in the areas of dermatology,
neurology and branded generics. More information about Valeant
Pharmaceuticals International, Inc. can be found at www.valeant.com
Forward Looking Statements
Certain statements contained in this presentation, other than statements of
fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Examples of such forward-looking statements
include those regarding cosmetics and medical devices and medical applications
and clinical trials and the status and related results thereto, as well those
regarding continuing and further development efforts. Such statements, based
as they are on the current analysis and expectations of management, inherently
involve numerous risks and uncertainties, known and unknown, many of which are
beyond KLOX Technologies Inc.'s control. Such risks include but are not
limited to: the impact of general economic conditions, general conditions in
the medical, cosmetics and/or consumer goods industries, changes in the
regulatory environment in the jurisdictions in which KLOX Technologies Inc.
does business, financial and commercial markets volatility, fluctuations in
costs, and changes to the competitive environment, as well as other risks.
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. In the case of
forward-looking statements regarding investigational product candidates and
continuing and further development efforts, specific risks which could cause
actual results to differ materially from KLOX Technologies Inc.'s current
analysis and expectations include: failure to demonstrate the safety,
tolerability and efficacy of our products, final and quality controlled
verification of data and the related analyses, and the expense and uncertainty
of obtaining regulatory approval.
Business, Consumer and Marketing Media: Roch Landriault NATIONAL Public
Relations +1 (514) 843-2345
SOURCE: Klox Technologies Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Klox Technologies Inc.
NI: MTC MNA
-0- Nov/29/2012 11:00 GMT
Press spacebar to pause and continue. Press esc to stop.